Received May 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
soreness at the site of injection; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 74-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Additional patient notes included patient other products and other conditions were unknown. On 16-APR-2026, the patient received the 2nd dose of Shingrix. In APR-2026, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: soreness at the site of injection). The outcome of the injection site pain was unknown. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Additional Information: GSK Receipt Date: 29-APR-2026 The reporter was the patient's wife. The batch number was not provided upon follow up with the reporter.
Comments: patient other products and other conditions were unknown